Cargando…
Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide
INTRODUCTION: Enzalutamide is approved for the treatment of patients with metastatic castration-resistant prostate cancer. Adverse effects (e.g., fatigue and anorexia) are often observed and cause difficulty with continuous therapy; however, no clinical data describing which patients are more likely...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646296/ https://www.ncbi.nlm.nih.gov/pubmed/36407065 http://dx.doi.org/10.31662/jmaj.2022-0096 |
_version_ | 1784827132782837760 |
---|---|
author | Kashiwagi, Eiji Shiota, Masaki Lee, Ken Monji, Keisuke Naganuma, Hidekazu Matsumoto, Takashi Takeuchi, Ario Inokuchi, Junichi Eto, Masatoshi |
author_facet | Kashiwagi, Eiji Shiota, Masaki Lee, Ken Monji, Keisuke Naganuma, Hidekazu Matsumoto, Takashi Takeuchi, Ario Inokuchi, Junichi Eto, Masatoshi |
author_sort | Kashiwagi, Eiji |
collection | PubMed |
description | INTRODUCTION: Enzalutamide is approved for the treatment of patients with metastatic castration-resistant prostate cancer. Adverse effects (e.g., fatigue and anorexia) are often observed and cause difficulty with continuous therapy; however, no clinical data describing which patients are more likely to suffer adverse effects were observed. Therefore, this study hypothesized that body composition, comprising body fat distribution and psoas muscle volume, may affect the occurrence of subjective symptoms (e.g., fatigue and anorexia) in prostate cancer patients treated with enzalutamide. METHODS: Adverse effects, especially fatigue, anorexia, insomnia, and pain, were retrospectively evaluated by CTCAE v4.0 criteria. Sixty-seven prostate cancer patients treated with enzalutamide were enrolled, and body fat, visceral fat percentage, and psoas muscle ratio (psoas muscle, in cubic centimeter/height, in meters) were calculated using computed tomography images evaluated before enzalutamide, with SYNAPSE VINCENT software. Univariate analysis was performed to identify the factors associated with adverse effects. RESULTS: Univariate analysis showed that high psoas muscle ratio was significantly associated with fatigue (grade ≥ 2; odds ratio, 3.875; 95% confidence interval, 1.016-17.134; P = 0.047), but inversely related to anorexia (grade ≥ 2; odds ratio, 0.093; 95% confidence interval, 0.011-0.784; P = 0.029). CONCLUSIONS: Psoas muscle ratio is a predictive marker of fatigue and anorexia in patients treated with enzalutamide. |
format | Online Article Text |
id | pubmed-9646296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Japan Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-96462962022-11-18 Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide Kashiwagi, Eiji Shiota, Masaki Lee, Ken Monji, Keisuke Naganuma, Hidekazu Matsumoto, Takashi Takeuchi, Ario Inokuchi, Junichi Eto, Masatoshi JMA J Original Research Article INTRODUCTION: Enzalutamide is approved for the treatment of patients with metastatic castration-resistant prostate cancer. Adverse effects (e.g., fatigue and anorexia) are often observed and cause difficulty with continuous therapy; however, no clinical data describing which patients are more likely to suffer adverse effects were observed. Therefore, this study hypothesized that body composition, comprising body fat distribution and psoas muscle volume, may affect the occurrence of subjective symptoms (e.g., fatigue and anorexia) in prostate cancer patients treated with enzalutamide. METHODS: Adverse effects, especially fatigue, anorexia, insomnia, and pain, were retrospectively evaluated by CTCAE v4.0 criteria. Sixty-seven prostate cancer patients treated with enzalutamide were enrolled, and body fat, visceral fat percentage, and psoas muscle ratio (psoas muscle, in cubic centimeter/height, in meters) were calculated using computed tomography images evaluated before enzalutamide, with SYNAPSE VINCENT software. Univariate analysis was performed to identify the factors associated with adverse effects. RESULTS: Univariate analysis showed that high psoas muscle ratio was significantly associated with fatigue (grade ≥ 2; odds ratio, 3.875; 95% confidence interval, 1.016-17.134; P = 0.047), but inversely related to anorexia (grade ≥ 2; odds ratio, 0.093; 95% confidence interval, 0.011-0.784; P = 0.029). CONCLUSIONS: Psoas muscle ratio is a predictive marker of fatigue and anorexia in patients treated with enzalutamide. Japan Medical Association 2022-09-20 2022-10-17 /pmc/articles/PMC9646296/ /pubmed/36407065 http://dx.doi.org/10.31662/jmaj.2022-0096 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Original Research Article Kashiwagi, Eiji Shiota, Masaki Lee, Ken Monji, Keisuke Naganuma, Hidekazu Matsumoto, Takashi Takeuchi, Ario Inokuchi, Junichi Eto, Masatoshi Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide |
title | Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide |
title_full | Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide |
title_fullStr | Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide |
title_full_unstemmed | Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide |
title_short | Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide |
title_sort | psoas muscle volume is a predictive marker of fatigue and anorexia in prostate cancer patients treated with enzalutamide |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646296/ https://www.ncbi.nlm.nih.gov/pubmed/36407065 http://dx.doi.org/10.31662/jmaj.2022-0096 |
work_keys_str_mv | AT kashiwagieiji psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT shiotamasaki psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT leeken psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT monjikeisuke psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT naganumahidekazu psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT matsumototakashi psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT takeuchiario psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT inokuchijunichi psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide AT etomasatoshi psoasmusclevolumeisapredictivemarkeroffatigueandanorexiainprostatecancerpatientstreatedwithenzalutamide |